IGFBP4 and inflammatory bowel disease: Additionally, PAPP-A is notoriously stimulated by pro-inflammatory cytokines, and thus, we hypothesized that IBD treatments, via their anti-inflammatory effects, may impinge on IGF-I activity via the STC2/PAPP-A/IGFBP-4-axis [26].